Cancer Genetics and Gilead Sciences, a big pharma company, are now biopharma partners where Cancer Genetics is providing clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.
CGI will leverage its SelectOne program that includes proprietary genomic assays in CLL, data and logistics management, and comprehensive CLIA- and CAP-accredited clinical laboratory testing.
The trials cover both national and international locations.
The ongoing studies consist of testing across several methodologies, including flow cytometry, FISH, and molecular diagnostics assays including mutational analyses of IGHV, TP53, NOTCH1, and CGI’s proprietary array-CGH assay for mature B-cell neoplasm, MatBA®-CLL/SLL.
Targeted therapies have the potential of improving the lives of cancer patients and providing them with better treatment outcome.
CGI’s SelectOne offering empowers biotech and pharma companies like Gilead to achieve their goals in oncology clinical trials through the use of CGI’s comprehensive oncology focused menu and proprietary microarrays.
CGI expects the trials to continue for the next several years, and may potentially enable an expedited and more efficient development timeline based on improved patient stratification.
CGI also offers comprehensive CLL testing to cancer centers, oncologists and community hospitals under its CLL CompleteSM offering.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Gilead Sciences
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity